Mirum Pharmaceuticals, Inc.
MIRM
$96.55
$3.914.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 521.31M | 471.79M | 429.16M | 379.25M | 336.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 521.31M | 471.79M | 429.16M | 379.25M | 336.89M |
| Cost of Revenue | 100.24M | 94.76M | 90.03M | 86.83M | 81.64M |
| Gross Profit | 421.07M | 377.04M | 339.14M | 292.42M | 255.25M |
| SG&A Expenses | 257.03M | 239.73M | 228.37M | 214.29M | 202.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 543.45M | 513.59M | 486.24M | 455.57M | 424.49M |
| Operating Income | -22.14M | -41.79M | -57.08M | -76.32M | -87.61M |
| Income Before Tax | -21.43M | -40.83M | -57.36M | -75.91M | -86.91M |
| Income Tax Expenses | 1.94M | 593.00K | 1.20M | 1.44M | 1.03M |
| Earnings from Continuing Operations | -23.36 | -41.42 | -58.56 | -77.34 | -87.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.36M | -41.42M | -58.56M | -77.34M | -87.94M |
| EBIT | -22.14M | -41.79M | -57.08M | -76.32M | -87.61M |
| EBITDA | 2.11M | -17.57M | -32.86M | -52.30M | -63.98M |
| EPS Basic | -0.47 | -0.86 | -1.22 | -1.62 | -1.86 |
| Normalized Basic EPS | -0.27 | -0.53 | -0.75 | -0.99 | -1.15 |
| EPS Diluted | -0.49 | -0.87 | -1.22 | -1.62 | -1.86 |
| Normalized Diluted EPS | -0.28 | -0.53 | -0.75 | -0.99 | -1.15 |
| Average Basic Shares Outstanding | 199.45M | 196.78M | 193.92M | 191.43M | 189.47M |
| Average Diluted Shares Outstanding | 205.81M | 203.13M | 193.92M | 191.43M | 189.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |